BFRG

Bullfrog AI Holdings, Inc. (BFRG) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Bullfrog AI Holdings, Inc. is a smaller reporting company and emerging growth company focused on using its proprietary AI/ML platform, bfLEAP, to analyze complex data sets in medicine and healthcare. The company aims to de-risk drug development through precision medicine approaches, strategic partnerships, and internal development of licensed drug assets.

Key Financial Metrics

Debt & Liquidity: Total current liabilities are $681,084, including $110,291 in short-term insurance financing. The company holds $105,000 in restricted cash. As of June 30, 2025, the company has an accumulated deficit of approximately $20.3 million.

Material Changes vs. Prior Period

• Revenue Generation: The company recognized $33,257 in revenue for the first time in 2025, derived from a single collaboration agreement with Eleison Pharmaceuticals Inc. This contrasts with $0 revenue in the comparable periods of 2024.
• Expense Reduction: Total operating expenses decreased by approximately $115,000 year-to-date compared to 2024. This was driven by reductions in personnel costs, director and officer (D&O) insurance premiums, and recruiting fees.
• Cash Position: Cash and cash equivalents decreased by approximately $2.9 million from the beginning of the year ($5.4M) to $2.5M at period end, reflecting continued negative operating cash flows.
• Financing Activity: Unlike the significant capital raises in 2024 (approx. $8.4M net proceeds from equity offerings), 2025 financing activity was limited to approximately $262,000 net proceeds from an At-The-Market (ATM) offering and $110,000 net from insurance financing.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management explicitly states that the current cash position is not sufficient to fund planned operations for at least one year beyond the filing date. This raises substantial doubt about the company's ability to continue as a going concern without additional financing.
• Capital Strategy: The company plans to raise additional capital through equity sales (including the ATM facility), debt, or licensing agreements. As of June 30, 2025, approximately $19.7 million of capacity remains under the ATM agreement, though SEC rules limit immediate sales to approximately $2.8 million based on public float.
• Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of June 30, 2025, due to unremediated material weaknesses in internal control over financial reporting. Remediation efforts are ongoing, including transitioning accounting processes to an external firm and enterprise platform.
• Strategic Focus: The company continues to pursue its strategy of generating revenue through biopharma collaborations and acquiring rights to drug assets to advance using its AI platform. It has active license agreements with JHU-APL, George Washington University, and Johns Hopkins University.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the current $2.5M cash balance against the stated burn rate and the timeline for securing the next round of financing.
• ATM Capacity Limits: Confirm the specific dollar amount available for immediate sale under the ATM agreement given the public float limitations mentioned ($2.8M cap).
• Revenue Sustainability: Assess the terms of the single revenue-generating contract with Eleison Pharmaceuticals to determine if it represents a recurring revenue stream or a one-time event.
• Internal Control Remediation: Monitor progress on fixing the material weaknesses in financial reporting, as this impacts the reliability of future financial statements.
• License Obligations: Review the accrued minimum royalty payments (e.g., $150,000 accrued for 2025 to JHU-APL) and ensure cash flow can cover these fixed obligations.